as 09-06-2024 4:00pm EST
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | IRVINE |
Market Cap: | 38.4M | IPO Year: | N/A |
Target Price: | $5.00 | AVG Volume (30 days): | 103.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.99 | EPS Growth: | N/A |
52 Week Low/High: | $0.71 - $17.17 | Next Earning Date: | 08-12-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AEON Breaking Stock News: Dive into AEON Ticker-Specific Updates for Smart Investing
Zacks
17 days ago
GlobeNewswire
19 days ago
GlobeNewswire
a month ago
MT Newswires
2 months ago
MT Newswires
2 months ago
GlobeNewswire
2 months ago
Zacks
3 months ago
GlobeNewswire
3 months ago
The information presented on this page, "AEON AEON Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.